Valuation: Corcept Therapeutics Incorporated

Market Cap 9.42B 8.42B 7.79B 7.05B 13.2B 896B 13.42B 93.76B 37.09B 469B 35.35B 34.59B 1,484B P/E 2026 *
42.8x
P/E 2027 * 21.1x
Enterprise Value 9.42B 8.42B 7.79B 7.05B 13.2B 896B 13.42B 93.76B 37.09B 469B 35.35B 34.59B 1,484B EV / Sales 2026 *
8.22x
EV / Sales 2027 * 5.62x
Free-Float
65.89%
Yield 2026 *
-
Yield 2027 * -
1 day+1.47%
1 week-22.28%
Current month-24.39%
1 month-24.96%
3 months-8.64%
6 months+89.16%
Current year+150.36%
1 week 84.13
Extreme 84.13
118.42
1 month 84.13
Extreme 84.13
122.81
Current year 28.66
Extreme 28.6601
126.38
1 year 28.66
Extreme 28.6601
126.38
3 years 20.84
Extreme 20.84
126.38
5 years 15.82
Extreme 15.825
126.38
10 years 6.68
Extreme 6.68
126.38
Manager TitleAgeSince
Chief Executive Officer 68 1998-12-31
Director of Finance/CFO 49 2021-02-28
Chief Tech/Sci/R&D Officer 48 2024-01-31
Director TitleAgeSince
Director/Board Member 68 1998-12-31
Chairman 82 1998-12-31
Director/Board Member 71 2004-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 Sell

Chairman

-10,000 0.0093%
10/2/26 Exercice

See Remarks

73,761 0.0682%
10/2/26 Exercice

Chief Technology Officer

27,570 0.0255%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%-22.28%+20.14%+216.13% 9.28B
+0.45%+3.13%+54.96%+125.16% 1,135B
+0.94%+4.93%+39.86%+78.72% 635B
+0.39%+1.44%+25.77%+97.48% 505B
+1.43%+4.31%+46.20%+67.12% 378B
-3.21%-2.10%+60.72%+33.22% 358B
-0.41%+2.64%+22.48%+49.82% 295B
+0.23%+3.66%+2.57%+23.69% 266B
+1.22%+4.63%+52.40%+64.85% 237B
+1.70%+3.67%+31.21%+102.15% 193B
Average +0.39%+0.28%+35.63%+85.84% 401.29B
Weighted average by Cap. +0.42%+2.79%+41.35%+83.91%

Financials

2026 *2027 *
Net sales 1.15B 1.02B 948M 859M 1.61B 109B 1.63B 11.41B 4.51B 57.03B 4.3B 4.21B 181B 1.68B 1.5B 1.39B 1.26B 2.35B 159B 2.39B 16.69B 6.6B 83.4B 6.29B 6.16B 264B
Net income 242M 216M 200M 181M 339M 22.98B 344M 2.4B 951M 12.02B 907M 887M 38.06B 568M 508M 470M 426M 797M 54.08B 810M 5.66B 2.24B 28.29B 2.13B 2.09B 89.56B
Net Debt - -
Projected Income Statement - Annual - Corcept Therapeutics Incorporated
Logo Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Employees
730
Date Price Change Volume
26-10-26 US$87.13 +1.47% 1,871,736
26-10-23 US$85.86 -20.13% 3,098,611
26-10-22 US$107.50 -7.55% 809,884
26-10-21 US$116.28 -0.15% 516,765
26-10-20 US$116.45 +3.88% 549,571
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Corcept Therapeutics Incorporated
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
87.12USD
Average target price
141.00USD
Spread / Average Target
+61.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Corcept Therapeutics Incorporated
  1. Stock Market
  2. Stocks
  3. CORT Stock